Skip to main content
Mayinglong Pharmaceutical Group Co.,Ltd logo

Mayinglong Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 600993 ISIN · CNE000001HN2 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 931 across all filing types
Latest filing 2023-04-07 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600993

About Mayinglong Pharmaceutical Group Co.,Ltd

https://www.mayinglong.cn/

Mayinglong Pharmaceutical Group Co.,Ltd. is a long-established enterprise specializing in the research, development, and production of Traditional Chinese Medicine (TCM). Founded in 1582, the company is widely recognized for its expertise in proctology, maintaining a dominant market position with its signature hemorrhoid ointments and suppositories. Its product portfolio also includes ophthalmic preparations, dermatological treatments, and gastrointestinal medicines. The company integrates traditional medicinal formulas with modern manufacturing technologies to provide healthcare solutions. Beyond pharmaceuticals, Mayinglong has expanded into healthcare services, including specialized hospitals and personal care products, focusing on the integration of clinical treatment and health management.

Recent filings

Filing Released Lang Actions
马应龙第十一届董事会第五次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 11th Board of Directors' 5th meeting of Mayinglong Pharmaceutical Group Co., Ltd. It includes approval of various 2022 annual reports such as the General Manager's report, Board work report, Independent Directors' report, Audit Committee report, financial statements, profit distribution plan, internal control evaluation report, and ESG report. It also discusses financial data for 2022, profit distribution, and other corporate governance matters. The document is not the full annual report itself but a board meeting resolution announcement that references the full reports published elsewhere. The document length is about 5112 characters, which is relatively short for a full annual report. The text states that the full reports are published on the Shanghai Stock Exchange website and newspapers. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is an official regulatory announcement of board meeting resolutions and approvals related to the annual report and other matters, not the full annual report itself.
2023-04-07 Chinese
马应龙2022年度审计委员会工作报告
Audit Report / Information Classification · 95% confidence The document is titled as the '2022年度审计委员会工作报告' which translates to '2022 Annual Audit Committee Work Report'. It details the audit committee's activities, including supervision of external auditors, internal audit guidance, review of financial reports, evaluation of internal controls, and coordination between management and auditors. The document is a standalone report focused on audit committee work and audit-related oversight, not a full annual report or financial statements. It does not contain full financial data or comprehensive company performance details typical of an Annual Report (10-K). It is not an announcement or certification but a substantive audit committee report. Therefore, it fits best under the category of Audit Report / Information (AR). The document length is 1599 characters, which is consistent with a detailed committee report rather than a brief announcement or certification. Confidence is high given the clear audit committee focus and content. FY 2022
2023-04-07 Chinese
马应龙关于为子公司提供贷款担保额度的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from the company 马应龙药业集团股份有限公司 regarding the provision of loan guarantees to its subsidiaries. It details the guarantee amounts, the subsidiaries involved, financial data of these subsidiaries, and the board's approval of the guarantee. The document includes specific financial figures and compliance statements but does not present a full financial report or earnings release. It is a formal disclosure about capital/financing activities related to guarantees provided to subsidiaries, which fits the category of Capital/Financing Update (CAP). The document length is over 6000 characters and contains substantive content about financing guarantees, not just a brief notice or certification. Therefore, the appropriate classification is CAP with high confidence.
2023-04-07 Chinese
马应龙2022年度非经营性资金占用及其他关联资金往来情况汇总表的专项审核报告
Audit Report / Information Classification · 95% confidence The document is titled as a "专项审计报告" which translates to a "Special Audit Report" concerning non-operating fund occupation and other related party fund transactions for the year 2022. It includes detailed tables of financial data related to these transactions and is issued by an audit firm. The content is focused on audit findings and financial details related to specific fund usage and related party transactions, which aligns with the definition of an Audit Report / Information (AR). The document length is 2169 characters, which is relatively short but contains substantive audit data rather than just an announcement or certification. Therefore, it is not a report publication announcement or a regulatory filing. It is a standalone audit report on a specific financial matter, fitting the AR category. FY 2022
2023-04-07 Chinese
马应龙独立董事关于第十一届董事会第五次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on various matters discussed at the company's 11th board meeting, including the 2022 profit distribution plan, internal control evaluation report, use of idle funds for entrusted wealth management, loan guarantees for subsidiaries, accounting policy changes, and appointment of the 2023 audit firm. It references the 2022 fiscal year and includes detailed opinions on financial and governance matters. The document is not the full annual report or audit report itself but an independent opinion related to board decisions and governance. It does not contain full financial statements or detailed financial data but focuses on board-level approvals and compliance with regulations. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of board decisions and management information.
2023-04-07 Chinese
马应龙独立董事关于第十一届董事会第五次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on various matters discussed at the company's 11th board meeting, including the 2022 profit distribution plan, internal control evaluation report, use of idle funds for entrusted wealth management, loan guarantees for subsidiaries, accounting policy changes, and appointment of the 2023 audit firm. It references the 2022 fiscal year and includes detailed opinions on financial and governance matters. The document is not a full annual report or audit report but rather a board/management related opinion document. It does not contain full financial statements or earnings highlights, nor is it a regulatory announcement or certification. Therefore, it fits best under Board/Management Information (MANG). The document length is 1708 characters, which is short but contains substantive content related to board decisions and opinions, not just an announcement or certification.
2023-04-07 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.